January 10, 2020
The Global Institute was honored to host Dr. Karl Lauterbach, an expert on Germany’s Pharmaceutical Market Reform Act (AMNOG). As a member of the Bundestag, Dr. Lauterbach was a leader in Germany’s drug pricing reform efforts and served as advisor to the prime minister on the subject. The intent of AMNOG is to control cost and ensure that drugs are evaluated carefully before entering the market. Assessments are based on patient- related outcomes, efficacy and safety measures, with pricing based on the drug’s performance relative to others in the same category. Fully transparent, the system aims for fair pricing for evidence-based quality drugs.